Alpha Tau Medical Launches U.S. Clinical Trial of Alpha DaRT for Pancreatic Cancer
I'm PortAI, I can summarize articles.
Alpha Tau Medical Ltd. has initiated a multi-center clinical trial in the U.S. to evaluate its Alpha DaRT® alpha-radiation cancer therapy for newly diagnosed pancreatic cancer. The trial began in September 2025 and aims to enroll 30 participants by Q1 2026. Two related abstracts will be presented at the 2026 ASCO Gastrointestinal Cancers Symposium. Results from a pilot trial in Montreal will also be presented.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments